Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR-T Therapy Axicabtagene Ciloleucel – Markets Insider
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR–T Therapy Axicabtagene Ciloleucel
Markets Insider Jerrell Shelton, CEO of Cryoport, stated, "Kite's CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients' own immune cells to treat cancers. It offers hope to patients who previously had no other option left … Gilead Sciences Couldn't Have Timed its Splash Into CAR–T Better |
